MARKET

INCY

INCY

Incyte Corp
NASDAQ
61.00
+0.47
+0.78%
After Hours: 61.37 +0.37 +0.61% 16:11 02/27 EST
OPEN
60.65
PREV CLOSE
60.53
HIGH
61.48
LOW
59.73
VOLUME
1.37M
TURNOVER
0
52 WEEK HIGH
78.02
52 WEEK LOW
50.27
MARKET CAP
13.70B
P/E (TTM)
23.06
1D
5D
1M
3M
1Y
5Y
Incyte's Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment
NASDAQ · 1h ago
FDA accepts Incyte application for graft-versus-host disease drug
Healthcare FDA accepts Incyte application for graft-versus-host disease drug. The agency is expected to issue a decision on the application by Aug. 28. Axatilimab is being developed with Syndax Pharmaceuticals (NASDAQ:SNDX)
Seeking Alpha · 5h ago
Incyte: A Potential GARP Superstar
Seeking Alpha · 17h ago
Weekly Report: what happened at INCY last week (0219-0223)?
Weekly Report · 1d ago
Incyte a new Buy at Jefferies on prospects beyond Jakafi
Jefferies launches coverage of Incyte Corporation with a Buy recommendation and $81 per share target. The analyst highlights the company's prospects beyond its top revenue generator, Jakafi. The JAK inhibitor added $2.6B in net revenue in 2023 and is expected to lose exclusivity in 2028.
Seeking Alpha · 4d ago
Stock Indexes Climb to Record Highs on a Tech Fueled Rally
S&P 500, Dow Jones Industrials, and Nasdaq 100 post new all-time highs. Nvidia is up more than +3% at a record high to lead a rally in technology stocks. Euro Stoxx 50 rises to a new 23-year high. A decline in global bond yields today is supportive of stocks.
Barchart · 4d ago
Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?
Moderna, Inc. (MRNA) is set to release its fourth-quarter 2023 results this Thursday. Shares of MRNA have plunged 11.7% over the past month. The biotech company recorded a sharp loss for the third quarter of 2023 due to plummeting demand for its COVID-19 vaccine.
Barchart · 02/20 07:02
Weekly Report: what happened at INCY last week (0212-0216)?
Weekly Report · 02/19 09:21
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.